MEI Pharma

MEI Pharma, Inc. is a clinical-stage biotechnology company focused on the development of targeted therapies for cancer treatment. The company's lead clinical candidate, voruciclib, is a CDK9 inhibitor under investigation for hematologic malignancies and solid tumors. MEI Pharma's oncology pipeline reflects a focus on small-molecule therapeutics that target specific mechanisms involved in cancer cell proliferation and survival.

Beyond its pharmaceutical operations, MEI Pharma has adopted a digital asset treasury strategy centered on Litecoin (LTC), making it among the first publicly listed U.S. companies to hold a cryptocurrency other than Bitcoin as a treasury reserve asset. This initiative positions the company at the intersection of biopharmaceutical development and digital asset adoption, supported by strategic investors from the cryptocurrency sector.

MEI Pharma operates within both the clinical-stage oncology segment of the biotechnology industry and the emerging category of public companies incorporating digital assets into corporate treasury management. The company's dual focus on cancer therapeutics development and cryptocurrency treasury strategy reflects an approach that combines traditional drug development with alternative financial positioning.